Is Xenon Pharmaceuticals Inc. (XENE) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.3% / 30% | 19.3% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 0.3% / 33% | 19.3% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 1.1% / 33% | 78.5% / 33% | 0.2% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.3% / 33% | 19.3% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 1.1% / 33% | 78.5% / 33% | 0.2% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -4974.3% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -51.8% | |
| Return on Assets (ROA) | -32.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$279M |
| Free Cash Flow | -$280M |
| Total Debt | $8M |
| Debt-to-Equity | 1.4 |
| Current Ratio | 13.4 |
| Total Assets | $633M |
Price & Trading
| Last Close | $55.53 |
| 50-Day MA | $46.42 |
| 200-Day MA | $40.28 |
| Avg Volume | 1.4M |
| Beta | 0.9 |
|
52-Week Range
$26.74
| |
About Xenon Pharmaceuticals Inc. (XENE)
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Xenon Pharmaceuticals Inc. (XENE) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Xenon Pharmaceuticals Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Xenon Pharmaceuticals Inc.'s debt ratio?
Xenon Pharmaceuticals Inc.'s debt ratio is 0.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.1%.
What are Xenon Pharmaceuticals Inc.'s key financial metrics?
Xenon Pharmaceuticals Inc. has a market capitalization of $5.2B, and revenue of $8M. Return on equity stands at -51.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.